VLDLR and fatty liver disease: Hepatic PPARβ/δ activation suppresses SREBP-1c,461 regulates the lipoprotein-related genes (VLDLR, ApoA5, ApoA4, and ApoC1), and enhances FAO, thereby reducing triglyceride and hepatic steatosis.462